Benfotiamine Prevents Vascular Dysfunction in Healthy Smokers

Ruhr University of Bochum

Status and phase: Completed; Phase 3

Conditions: Healthy Subjects

Treatments: Drug: Benfotiamine

Study type: Interventional

Funder types: Other

Identifiers

NCT00785460

Benfo Smoker

Details and patient eligibility

About

Benfotiamine pretreatment (3 days)at high dosage (1050 mg/day) prevents in healthy subjects smoking-induced vascular dysfunction assessed by ultrasound flow mediated dilatation of the brachial artery.

Full description

Benfotiamine pretreatment (3 days)at high dosage (1050 mg/day) prevents in healthy subjects smoking-induced vascular dysfunction assessed by ultrasound flow mediated dilatation (FMD) of the brachial arteryand laboratory parameters (adhesion molecules).

Enrollment: 20 patients

Sex: All

Ages: 20 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• healthy habitual smokers

Exclusion criteria

• any kind of chronic disease

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Single Blind

---

20 participants in 2 patient groups, including a placebo group

Benfotiamine and Smoking

Experimental group

Treatment:

Drug: Benfotiamine

Smoking alone

Placebo Comparator group

Treatment:

Drug: Benfotiamine